Part One: Identifying Challenges In LVV Purification And Quantitation

By Poorni Adikaram, Ph.D., Tyler Frazier, and Timothy Fouts, Ph.D., CSO, at ABL Inc- . and Rebecca Montange, Ph.D, and Brandon Harrell at Sartorius

Growing demand for lentiviral vectors (LVVs) is creating the need for robust, scalable, GMP manufacturing processes. Accelerating process development can be difficult, however, due to a lack of rapid, reliable methods for LVV quantification. The Virus Counter® Plus platform (Sartorius) using the Virotag® VSVG assay enables quick (near-real-time) and precise determination of total particle counts and therefore supports rapid development of high-performing processes.

In this 3-part blog series, scientists from ABL, Inc. discuss the issues with current titer measurement methods, describe the Virus Counter Plus platform, and present highlights of a recent study conducted in collaboration with Sartorius to assess the correlation of titer data obtained using the new method to that generated using traditional physical and functional titer assays.